Integrity of the CBL gene in mature B-cell malignancies.


Identification of biomarkers for response to novel therapeutic agents is an essential step for the success of tailored treatments in cancer. Preliminary data from clinical trials indicate that inhibitors of the spleen tyrosine kinase (SYK) may be efficacious in subsets of diffuse large B-cell lymphomas (DLBCL) and chronic lymphocytic leukemias (CLL).1 SYK… (More)
DOI: 10.1182/blood-2009-08-239988